YEIDA Grants Intent Letter for Major Medical Technology Manufacturing Facility in Noida
The Yamuna Expressway Industrial Development Authority (YEIDA) has taken a significant step toward bolstering India's medical technology sector by issuing a formal Letter of Intent (LoI) to Shukra Pharmaceuticals. This authorization paves the way for the establishment of a state-of-the-art manufacturing plant dedicated to advanced medical technologies.
Strategic Investment and Location Details
The proposed facility will be strategically located within the Medical Devices Park in Sector 28, Noida, covering an expansive area of 10 acres. This development falls under the ambitious Invest UP initiative, which aims to attract substantial industrial investments to Uttar Pradesh. Shukra Pharmaceuticals has committed a formidable investment of Rs 587 crore to bring this project to fruition, signaling strong confidence in the region's industrial ecosystem.
Pioneering Cancer Treatment and Diverse Medical Equipment Production
A cornerstone of this project will be the production of Boron Neutron Capture Therapy (BNCT) systems. This innovative technology represents one of the most sophisticated treatment modalities available for complex and challenging cancer cases, offering new hope for patients. Beyond this, the facility will manufacture a comprehensive range of radiology and imaging equipment, including:
- CT scanners and MRI systems
- PET scanners and advanced X-ray machines
- Ultrasound devices and related diagnostic tools
The plant will also produce critical care equipment such as anaesthesia systems and respiratory care solutions specifically designed for intensive care units and operating theatres. In the realm of cardiac care, the facility will manufacture essential implants including heart valves, stents, and left ventricular assist devices (LVADs) to support treatment of severe heart conditions.
Enhancing Healthcare Infrastructure and Employment Generation
This project is expected to make a substantial impact on local employment, with projections indicating the creation of over 900 direct jobs and approximately 2,000 indirect employment opportunities. These positions will span various domains including manufacturing, research and development, quality control, regulatory affairs, sales, and allied support services. Officials have emphasized a strong focus on local hiring and skill development initiatives, which will help reduce import dependence while improving access to affordable, world-class medical devices within the country.
Advanced Medical Robotics and Diagnostic Solutions
Another significant focus area for the facility will be the development and manufacturing of cutting-edge medical robotics. The planned production includes:
- Soft-tissue surgical robots for delicate procedures
- Orthopaedic robotic systems for bone-related surgeries
- Dental robotic systems for precision dentistry
- Neuro-spine robotic platforms for complex neurological interventions
These robotic systems aim to dramatically improve surgical precision and patient outcomes. Additionally, the company plans to manufacture in-vitro diagnostic solutions, including point-of-care testing devices and advanced analysers, to enable faster and more accurate medical diagnoses.
Training Infrastructure and Project Handover
The facility will also establish medical simulators for training doctors, nurses, and paramedical staff, enhancing clinical skills while reducing patient risk during actual procedures. The formal LoI handover ceremony took place on Tuesday in the presence of key officials including YEIDA CEO Rakesh Kumar Singh, additional CEO Shailendra Bhatia, and senior representatives from Shukra Pharmaceuticals led by group CEO and global head Dr Minakshi Late, along with chief operating officer Gaurav Shokeen, vice-president Anil Kumar Verma, and business unit head Kamini Bharti.
Medical Devices Park Progress and Broader Impact
The Medical Devices Park itself, spanning over 350 acres along the Yamuna Expressway, is currently approximately 80% complete with full completion targeted by the end of 2026. The park has already attracted investment commitments exceeding Rs 1,200 crore, with land allotment completed for 101 companies demonstrating robust industry response. This new facility by Shukra Pharmaceuticals represents a significant addition to this growing medical technology hub, promising to strengthen India's healthcare manufacturing capabilities while creating substantial economic opportunities in the Noida region.
